Supporting our hypothesis that miR-429 has an oncogenic role, recent several studies have exhibited that it can promote the carcinogenesis of pancreatic ductal adenocarcinoma, gastric cancer, and colorectal cancer by targeting EP-300, SOX2, or c-myc [15, 16, 42], while the inhibitors of miR-429 significantly suppressed such tumor cells as of endometrial cancer cells and gastric cancer cell proliferation. The gene discussed is MYC; the disease is pancreatic ductal adenocarcinoma.